SynthesisHepatology communications2023
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis.
Synthesis in Hepatology communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation.Hepatology (Baltimore, Md.) · 2026Guideline
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatology international · 2024Guideline
- Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Pooled it
- Trial
- Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study.Asian Pacific journal of cancer prevention : APJCP · 2024Trial
- Exploratory Comparison of Meld, Meld-Na, and Meld 3.0 Scores for Prognostic Assessment at Diagnosis in Hepatocellular Carcinoma Using Machine Learning Approaches.Digestive diseases and sciences · 2026Article
- Multidisciplinary Tumor Board Documentation: Assessing its Frequency, Quality, and Impact.Annals of surgical oncology · 2026Article
- Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- Artificial intelligence (AI)-assisted full-course case management for primary liver cancer: System design, preliminary implementation, and practical considerations.Global health & medicine · 2026Article
- Causes of mortality among patients with early-stage hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2026Article
- PHENO-RAG: An artificial intelligence tool for guideline-informed management decisions in hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2026Article
- Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study.Liver cancer · 2026Article
- Social Determinants of Health Are Associated With Treatment Receipt and Mortality in Patients With Hepatocellular Carcinoma.Journal of the National Comprehensive Cancer Network : JNCCN · 2026Article
- Factors associated with unmet psychological care needs and development of a Neuman systems model-based risk prediction model in patients with hepatocellular carcinoma.Frontiers in psychiatry · 2026Article
- Management of hepatocellular carcinoma prior to liver transplantation: latest developments.Hepatic oncology · 2025Review
- Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide.JCO oncology practice · 2025Review
- Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma.Gastroenterology · 2025Review
- Article
- Article
- Improving Health-Related Quality of Life in Hepatocellular Carcinoma Patients: Key Methodologies for Assessing Patient Reported Outcomes and Intervention Targets.Journal of hepatocellular carcinoma · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundGiven the complexity of managing HCC, professional society guidelines advocate multidisciplinary care (MDC) for patients with HCC. However, implementation of MDC programs requires a significant investment of time and resources. We conducted a systematic review and meta-analysis to enumerate potential benefits of MDC for patients with HCC.
methodsWe conducted a search of the PubMed/MEDLINE and EMBASE databases and national conference abstracts to identify studies published after January 2005 that reported early-stage presentation, treatment receipt, or overall survival among patients with HCC, stratified by MDC status. We calculated pooled risk ratios and HRs for clinical outcomes according to MDC receipt using the DerSimonian and Laird method for random effects models.
resultsWe identified 12 studies (n = 15,365 patients with HCC) with outcomes stratified by MDC status. MDC was associated with improved overall survival (HR = 0.63, 95% CI: 0.45-0.88); however, its association with curative treatment receipt was not statistically significant (risk ratio = 1.60, 95% CI: 0.89-2.89) and pooled estimates were limited by high heterogeneity (I2 > 90% for both). Studies (n = 3) were discordant regarding an association between MDC and time-to-treatment initiation. MDC was associated with early-stage HCC (risk ratio = 1.60, 95% CI: 1.12-2.29), suggesting possible referral bias contributing to improved outcomes. Limitations of studies also included risk of residual confounding, loss to follow-up, and data preceding the availability of immune checkpoint inhibitors.
conclusionMDC for patients with HCC is associated with improved overall survival, underscoring the likely benefit of managing patients with HCC in a multidisciplinary care setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.